Policy analysis for end-stage renal disease in Jamaica

Social Science and Medicine

Volumn 49, Issue 7, 1999, Pages 905-920

  Trisolini, M ^a   Ashley, D ^b   Harik, V ^a   Bicknell, W ^a  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b Ministry of Health   (Jamaica)

Author keywords

Chronic diseases; Developing countries; End stage renal disease; Policy analysis

Indexed keywords

DISEASE CONTROL; HEALTH POLICY; POLICY ANALYSIS;

ARTICLE; BUDGET; COST BENEFIT ANALYSIS; COST CONTROL; DEVELOPING COUNTRY; GOVERNMENT; HEALTH CARE FINANCING; HEALTH CARE POLICY; HEALTH EDUCATION; HUMAN; INCOME; JAMAICA; KIDNEY FAILURE; RESOURCE ALLOCATION; SOCIOECONOMICS;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; HEALTH CARE RATIONING; HEALTH POLICY; HEALTH PRIORITIES; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; JAMAICA; KIDNEY FAILURE, CHRONIC;

JAMAICA;

EID: 0032838530     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0277-9536(99)00177-X     Document Type: Article

References (58)

1. Anthony R., Young D. Management Control in Nonprofit Organizations. Fifth ed. 1995;Richard Irwin, Inc, Homewood, Illinois.
2. Armstrong, J. 1994 Jamaica Health Sector Review: Present Status and Future Options. Report No. 13407-JM. World Bank, Washington.
3. Basinda S., Maro E., McLarty D., Young A., Wing A. Ten Tanzanian transplants: problems and perspectives. Postgraduate Medical Journal. 64:1988;778-782.
4. Benjamin M. Letter to the editor. New England Journal of Medicine. 331:1994;813.
5. Benjamin M., Cohen L., Grochowski E. What transplantation can teach us about health care reform. New England Journal of Medicine. 330:1994;858-860.
6. Bicknell W. Jamaican Health Sector Assessment: Policy Implications & Recommendations. 1994;Center for International Health, Boston University, Boston.
7. Bicknell W. End Stage Renal Disease: Policy Options for Jamaica. 1994;Center for International Health, Boston University, Boston.
8. Bicknell W., Parks C.L. As children survive: dilemmas of aging in the developing world. Social Science & Medicine. 28:1989;59-67.
9. Blumstein J. The Oregon experiment: the role of cost-benefit analysis in the allocation of Medicaid funds. Social Science & Medicine. 45:1997;545-554.
10. Borrero-Ramirez J. End-stage renal disease in Latin America: socioeconomic aspects of its therapy. Contributions to Nephrology. 71:1989;169-171.
11. Brownlee A. Promoting Health Systems Research As A Management Tool. 1991;International Development Research Centre, Ottawa.
12. Challu A., Martinez-Maldonado M. Latin American nephrology: present state and future concerns. Kidney International. 52:1997;583-588.
13. Dalela D., Bhandari M., Kumar A., Kher V., Sharma R. Creation of low-cost model of renal transplantation suitable for developing countries. Transplantation Proceedings. 24:1992;2129.
14. Friedman E. Nephrology and the rationing of health care. Contributions to Nephrology. 102:1993;220-236.
15. Giatras I., Lau J., Levey A. Effect of angio-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Annals of Internal Medicine. 127:1997;337-345.
16. Hadorn D. Setting health care priorities in Oregon: cost-effectiveness analysis meets the rule of rescue. Journal of the American Medical Association. 265:1991;2218-2225.
17. Hadorn D. The Oregon priority-setting exercise: cost-effectiveness and the rule of rescue, revisited. Medical Decision Making. 16:1996;117-119.
18. Harik, V., Trisolini, M. 1994 JHEALTH Model , Version 2.0, Volume 2. Center for International Health, Boston University, Boston.
19. Held P., Turenne M., Borbjerg R. Cost Effectiveness of ESRD Treatment Modalities. 1992;The Urban Institute, Washington.
20. Iglehart J. The American health care system: the end stage renal disease program. New England Journal of Medicine. 328:1993;366-371.
21. Ikels C. Kidney failure and transplantation in China. Social Science & Medicine. 44:1997;1271-1283.
22. Country and support group reports. INRUD News: Newsletter of the International Network for the Rational Use of Drugs. 5:1995;8-12.
23. Jacobs C. The cost of dialysis treatments for patients with end-stage renal disease in France. Nephrology Dialysis Transplantation. 12:(Supplement 1):1997;29-32.
24. Kjellstrand C., Moody H. Hemodialysis in Canada: a first-class medical crisis. Canadian Medical Association Journal. 150:1994;1067-1071.
25. Lasker R. The Diabetes Control and Complications Trial: implications for policy and practice. New England Journal of Medicine. 329:1993;1035-1036.
26. Levinsky N. The organization of medical care: lessons from the Medicare end stage renal disease program. New England Journal of Medicine. 329:1993;1395-1399.
27. Lockhart C., Harik V. Chronic Disease and Adult Illness. 1994;Center for International Health, Boston University, Boston.
28. Luke R. New issues in therapy after renal transplantation. New England Journal of Medicine. 331:1994;393-394.
29. Mackenzie H., Brenner B. Current strategies for retarding progression of renal disease. American Journal of Kidney Diseases. 31:1998;161-170.
30. McCaw-Binns A., et al. Registration of births, stillbirths and infant deaths in Jamaica. International Journal of Epidemiology. 25:1996;807-813.
31. Mendez R., et al. Costs and financing of kidney transplantation in the United States. Transplantation Proceedings. 24:1992;2127-2128.
32. Miller D. Handbook of Research Design and Social Measurement. 1991;Sage Publications, Newbury Park, California.
33. Mitchell S., et al. Can we afford to transplant? Medical Journal of Australia. 158:1993;190-194.
34. Naqvi S., Hussain M., Askari H., Hashmi A., Hussain Z., Hussain I, Hafiz S., Yazdani I, Razvi S. Economics of renal rehabilitation in Pakistan: a case for increasing transplantation activity. Transplantation Proceedings. 24:1992;2125-2126.
35. Otten J. Letter to the editor. New England Journal of Medicine. 331:1994;813.
36. Pearson T., Jamison D., Trejo-Gutierrez J.T. Cardiovascular disease. Disease Control Priorities in Developing Countries. 1993;577-594 Oxford University Press, New York.
37. Petitti D. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis. 1994;Oxford University Press, New York.
38. Phillips D. Does the epidemiological transition have utility for health planners? Social Science & Medicine. 38:1994;vii-x.
39. Piccoli G., Formica M., Mangiarotti G. The costs of dialysis in Italy. Nephrology Dialysis Transplantation. 12:(Supplement 1):1997;33-44.
40. PIOJ, 1991. Survey of Living Conditions 1991. Planning Institute of Jamaica, Kingston.
41. PIOJ, 1993. Economic and Social Survey, Jamaica 1992. Planning Institute of Jamaica, Kingston.
42. Prichard S. Socioeconomic and health-care policies and peritoneal dialysis. Peritoneal Dialysis International. 16:(Supplement 1):1996;S378-S380.
43. Rashid H., Rahman M., Wahab M, Kibria G., Iqbal K. Renal transplantation in Bangladesh. Transplantation Proceedings. 27:1995;1461-1462.
44. Rennie D., Rettig R., Wing A. Limited resources and the treatment of end-stage renal failure in Britain and the United States. Quarterly Journal of Medicine. 5:1985;321-336.
45. Sanfilippo F. HLA matching in renal transplantation. New England Journal of Medicine. 331:1994;803-805.
46. Schena F. Report on the first meeting of the chairmen of the national and international registries. Kidney International. 52:1997;1422.
47. Sesso R., et al. Cost-effectiveness analysis of the treatment of end-stage renal disease in Brazil. International Journal of Technology Assessment in Health Care. 6:1990;107-114.
48. Steinman T. Kidney protection: how to prevent or delay chronic renal failure. Geriatrics. 51:1996;28-35.
49. Suthanthiran M., Strom T. Renal transplantation. New England Journal of Medicine. 331:1994;365-376.
50. Trisolini M. Methods for cost analysis, cost recovery, and cost control for a public hospital in a developing country: Victoria Hospital, St Lucia. International Journal of Health Planning and Management. 7:1992;103-132.
51. Turcotte J., Rapaport F., Dossetor J. Global review of transplantation practices. Transplantation Proceedings. 22:1990;906-907.
52. US Renal Data System, 1994. USRDS 1994 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland.
53. US Renal Data System, 1998. USRDS 1998 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland.
54. van Zyl-Smit R., Pascoe M. Where do we go from here - the future of nephrology in South Africa. South African Medical Journal. 87:1997;591-594.
55. Walt G., Gilson L. Reforming the health sector in developing countries: the central role of policy analysis. Health Policy and Planning. 9:1994;353-370.
56. Woo K. Renal replacement therapy in Singapore. Contributions to Nephrology. 82:1990;6-14.
57. World Bank 1993 World Development Report 1993. Oxford University Press, New York.
58. World Bank 1997 World Development Report 1997. Oxford University Press, New York.